Computational modeling and experimental evaluation of a novel prodrug for targeting the extracellular space of prostate tumors

Cancer Research

Volumn 67, Issue 5, 2007, Pages 2197-2205

  Pospisil, Pavel ^a   Wang, Ketai ^a   Al Aowad, Ayman F ^a   Iyer, Lakshmanan K ^b   Adelstein, S James ^a   Kassis, Amin I ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2' HYDROXYPHENYL) 6 IODO 4 (3H) QUINAZOLINONE I 125; ACID PHOSPHATASE PROSTATE ISOENZYME; ALPHA BENZYLAMINOBENZYLPHOSPHONIC ACID; AMMONIUM 2 (2' PHOSPHORYLOXYPHENYL) 6 IODO 4 (3H) QUINAZOLINE; AMMONIUM 2 (2' PHOSPHORYLOXYPHENYL) 6 IODO 4 (3H) QUINAZOLINE I 125; PHOSPHONIC ACID DERIVATIVE; QUINAZOLINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; HUMAN; HUMAN CELL; HYDROLYSIS; IMAGING SYSTEM; ISOTOPE LABELING; MOLECULAR DOCKING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RADIOIODINATION;

CARCINOMA; COMPUTER SIMULATION; DRUG DELIVERY SYSTEMS; EXTRACELLULAR SPACE; HUMANS; IODINE RADIOISOTOPES; MALE; MODELS, BIOLOGICAL; MODELS, MOLECULAR; PRODRUGS; PROSTATIC NEOPLASMS; PROTEIN-TYROSINE-PHOSPHATASE; QUATERNARY AMMONIUM COMPOUNDS; QUINAZOLINONES; TUMOR CELLS, CULTURED;

EID: 33947236862     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3309     Document Type: Article

References (49)

1. Ho N, Harapanhalli RS, Dahman BA, et al. Synthesis and biologic evaluation of a radioiodinated quinazolinone derivative for enzyme-mediated insolubilization therapy. Bioconjugate Chem 2002;13:357-64.
2. Pospisil P, Iyer LK, Adelstein SJ, Kassis AI. A combined approach to data mining of textual and structured data to identify cancer-related targets. BMC Bioinformatics 2006;7:354.
3. Chen K, Wang K, Kirichan AM, et al. In silico design, synthesis, and biological evaluation of radioiodinated quinazolinone derivatives for alkaline phosphatase-mediated cancer diagnosis and therapy. Mol Cancer Ther 2006;5:3001-13.
4. Chen K, Al Aowad AF, Adelstein SJ, Kassis AI. Molecular-docking-guided design, synthesis, and biological evaluation of radioiodinated quinazolinone prodrugs for alkaline-phosphatase-mediated insolubilization in diagnosis and therapy. J Med Chem. In press 2007.
5. Wang K, Kirichan AM, Al Aowad AF, Adelstien SJ, Kassis AI. Evaluation of chemical, physical and biological properties of tumor-targeting radioiodinated quinazolinone derivative. Bioconjugate Chem. In press 2007.
6. Benham FJ, Harris H. Human cell lines expressing intestinal alkaline phosphatase. Proc Natl Acad Sci U S A 1979;76:4016-9.
7. Benham FJ, Fogh J, Harris H. Alkaline phosphatase expression in human cell lines derived from various malignancies. Int J Cancer 1981;27:637-44.
8. Nadji M, Morales AR. Immunohistochemical markers for prostatic cancer. Ann N Y Acad Sci 1983;420:134-9.
9. Stein BS, Vangore S, Petersen RO. Immunoperoxidase localization of prostatic antigens: comparison of primary and metastatic sites. Urology 1984;24:146-52.
10. Oxley JD, Abbott CD, Gillatt DA, MacIver AG. Ductal carcinomas of the prostate: a clinicopathological and immunohistochemical study. Br J Urol 1998;81:109-15.
11. Brenckman WD, Jr., Lastinger LB, Sedor F. Unpredictable fluctuations in serum acid phosphatase activity in prostatic cancer. JAMA 1981;245:2501-4.
12. Loor R, Wang MC, Valenzuela L, Chu TM. Expression of prostatic acid phosphatase in human prostate cancer. Cancer Lett 1981;14:63-9.
13. Mulders PFA, Fernandez del Moral P, Theeuwes AGM, Oosterhof GON, van Berkel HTH, Debruyne FMJ. Value of biochemical markers in the management of disseminated prostatic cancer. Eur Urol 1992;21:2-5.
14. Wirth MP, Frohmüller HGW. Prostate-specific antigen and prostatic acid phosphatase in the detection of early prostate cancer and in the prediction of regional lymph node metastases. Eur Urol 1992;21:263-8.
15. Moss DW, Raymond FD, Wile DB. Clinical and biological aspects of acid phosphatase. Crit Rev Clin Lab Sci 1995;32:431-67.
16. Vitali A, Ardoino S, Durante P, et al. Correlation between immunohistochemical patterns and serum levels of PSA and PSAP in prostatic pathology: evaluation of 198 prostatic fine needle biopsies. Anticancer Res 1994;14:1503-7.
17. Ortlund E, LaCount MW, Lebioda L. Crystal structures of human prostatic acid phosphatase in complex with a phosphate ion and α- benzylaminobenzylphosphonic acid update the mechanistic picture and offer new insights into inhibitor design. Biochemistry (Mosc) 2003;42:383-9.
18. Schneider G, Lindqvist Y, Vihko P. Three-dimensional structure of rat acid phosphatase. EMBO J 1993;12:2609-15.
19. Lin M-F, Clinton GM. Human prostatic acid phosphatase has phosphotyrosyl protein phosphatase activity. Biochem J 1986;235:351-7.
20. Rönnberg L, Vihko P, Sajanti E, Vihko R. Clomiphene citrate administration to normogonadotropic subfertile men: blood hormone changes and activation of acid phosphatase in seminal fluid. Int J Androl 1981;4:372-8.
21. Eerdekens MW, Nouwen EJ, Pollet DE, Briers TW, De Broe ME. Placental alkaline phosphatase and cancer antigen 125 in sera of patients with benign and malignant diseases. Clin Chem 1985;31:687-90.
22. Shih W-J, Gross K, Mitchell B, et al. Prostate adenocarcinoma using Gleason scores correlates with prostate-specific antigen and prostate acid phosphatase measurements. J Natl Med Assoc 1992;84:1049-50.
23. Beers SA, Schwender CF, Loughney DA, Malloy E, Demarest K, Jordan J. Phosphatase inhibitors - III. Benzylaminophosphonic acids as potent inhibitors of human prostatic acid phosphatase. Bioorg Med Chem 1996;4:1693-701.
24. Porvari KS, Herrala AM, Kurkela RM, et al. Site-directed mutagenesis of prostatic acid phosphatase: catalyticaliy important aspartic acid 258, substrate specificity, and oligomerization. J Biol Chem 1994;269:22642-6.
25. Lindqvist Y, Schneider G, Vihko P. Crystal structures of rat acid phosphatase complexed with the transition-state analogs vanadate and molybdate: implications for the reaction mechanism. Eur J Biochem 1994;221:139-42.
26. Moss DW. Fetal intestinal alkaline phosphatase in serum and amniotic fluid. Clin Biochem 1987;20:393-8.
27. De Broe ME, Pollet DE. Multicenter evaluation of human placenta! alkaline phosphatase as a possible tumor-associated antigen in serum. Clin Chem 1988;34:1995-9.
28. Moss DW. Perspectives in alkaline phosphatase research. Clin Chem 1992;38:2486-92.
29. Fishman WH. The 1993 ISOBM Abbott Award Lecture. Isozymes, tumor markers, and oncodevelopmental biology. Tumor Biol 1995;16:394-402.
30. Fontana A, Delmas PD. Markers of bone turnover in bone metastases. Cancer 2000;88:2952-60.
31. Shih L-Y, Shih H-N, Chen T-H. Bone resorption activity of osteolytic metastatic lung and breast cancers. J Orthop Res 2004;22:1161-7.
32. San Francisco IF, Olumi AF, Yoon JH, Regan MM, DeWolf WC. Preoperative serum acid phosphatase and alkaline phosphatase are not predictors of pathological stage and prostate-specific antigen failure after radical prostatectomy. BJU Int 2003;92:924-8.
33. Garde SV, Sheth AR, Porter AT, Pienta KJ. A comparative study on expression of prostatic inhibin peptide, prostate acid phosphatase, and prostate specific antigen in androgen independent human and rat prostate carcinoma cell lines. Cancer Lett 1993;70:159-66.
34. Garde SV, Sheth AR, Venkatesan VM, Panchal CJ, Porter AT, Grignon DJ. Prostate inhibin peptide (PIP) in prostate cancer: a comparative immunohistochemical study with prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP). Cancer Lett 1994;78:11-7.
35. Mitchell S, Abel P, Ware M, Stamp G, Lalani E-N. Phenotypic and genotypic characterization of commonly used human prostatic cell lines. BJU Int 2000;85:932-44.
36. Horoszewicz JS, Leong SS, Kawinski E, et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809-18.
37. Andrews PE, Young CY-F, Montgomery BT, Tindall DJ. Tumor-promoting phorbol ester down-regulates the androgen induction of prostate-specific antigen in a human prostatic adenocarcinoma cell line. Cancer Res 1992;52:1525-9.
38. Lin M-F, Garcia-Arenas R, Kawachi M, Lin F-F. Regulation of the expression of prostatic acid phosphatase in LNCaP human prostate carcinoma cells. Cell Mol Biol Res 1993;39:739-50.
39. Warburg O. The metabolism of tumours. London (UK): Arnold Constable; 1930.
40. 31P NMR spectroscopy. NMR Biomed 1990;3:233-8.
41. 31P nuclear magnetic resonance spectroscopy. Cancer Res 1992;52:1259-66.
42. 31P magnetic resonance spectroscopy. Biochem Pharmacol 1999;57:309-12.
43. 31P-MRS measurements of extracellular pH of tumors using 3-aminopropylphosphonate. Am J Physiol 1994;267:C195-203.
44. 31P magnetic resonance spectroscopy in murine tumours. Br J Cancer 1995;72:905-11.
45. Schwickert G, Walenta S, Sundfør K, Rofstad EK, Mueller-Klieser W. Correlation of high lactate levels in human cervical cancer with incidence of metastasis. Cancer Res 1995;55:4757-9.
46. Walenta S, Wetterling M, Lehrke M, et al. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res 2000;60:916-21.
47. Brizel DM, Schroeder T, Scher RL, et al. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;51:349-53.
48. Roy AV, Brower ME, Hayden JE. Sodium thymolphthalein monophosphate: a new acid phosphatase substrate with greater specificity for the prostatic enzyme in serum. Clin Chem 1971;17:1093-102.
49. Fishman WH, Ghosh NK. Isoenzymes of human alkaline phosphatase. Adv Clin Chem 1967;10:255-370.